-+ 0.00%
-+ 0.00%
-+ 0.00%
Morgans just bumped up its price target for this booming ASX financials stock
Share
Listen to the news

Solvar Ltd (ASX: SVR) has been an outstanding ASX financials stock to own over the last year. 

It is a financial services company specialising in providing finance and other related services to assist consumers with the purchase of a new or used vehicle, as well as offering personal loans to consumers.

12 months ago Solvar shares were trading for roughly $1.38. 

Yesterday, this ASX financials stock closed at $1.86. 

That's a rise of 34%.

For context, the S&P/ASX 200 Index (ASX: XJO) is up roughly 7.9% in that same span. 

On Wednesday, the company released H1 FY26 results.

Let's see what the company reported. 

Earnings growth 

In Wednesday's announcement, for the half year ended 31 December 2025 (H1 FY26), the company reported: 

  • Normalised Net Profit After Tax (NPAT) of $20.0 million, up 5.8% on pcp;
  • Statutory NPAT of $17.8 million, up 5.8% on pcp;
  • Earnings Per Share (EPS) up 13.5% to 9.3 cents per share on pcp;
  • Fully franked interim dividend of 6.0 cents, plus a special fully franked dividend of 2.5 cents per share, totalling 8.5 cents per share payable on 7 April 2026.

Solvar also reiterated FY26 guidance of normalised NPAT of $36.0 million (including the one-off sale of the written off loan book in New Zealand).

Speaking on the outlook, Mr Scott Baldwin, CEO and Managing Director of Solvar said:

Solvar continues to invest in the development of new products and establishing a dedicated commercial lending team, with the commercial loan book now at ~$67.0 million and growing. Solvar anticipates continued growth in commercial lending as Bennji establishes itself in the market.

Investors were clearly pleased with the results as its share price is up 5.6% since the announcement. 

Morgans gives it an upgrade

Following the result, the team at Morgans increased its target price on this ASX financials stock. 

The broker said the company's 1H26 result continued to illustrate the ongoing shift in the business as management work through the windup of New Zealand and refocus attention back towards domestic growth. 

Normalised NPAT was ahead of estimates, while net interest income was behind. 

FY26 Normalised NPAT guidance of ~$36m (i.e. NPAT of $34m plus ~$2m from one-off sale of NZ Arrears) was reiterated (implying 2H NPAT of $16m), with SVR expecting book growth momentum to improve into 2H26 lead by Bennji & AFS. Our FY26-28F Underlying NPAT forecasts lift by +5%/+1%/+1%.

Following this forecast upgrade, the broker increased the price target to $2.00 (previously $1.85). 

Morgans maintained its Accumulate rating. 

Based on yesterday's closing price of $1.86, the new price target indicates an upside of 7.53%

The post Morgans just bumped up its price target for this booming ASX financials stock appeared first on The Motley Fool Australia.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending